Roflumilast
Roflumilast is a PDE4 inhibitor, an NSAID for the treatment of COPD. It acts by antagonizing the PDE4.
Primary Characteristics
It is of Synthetic origin.
It belongs to PDE4 Inhibitor pharmacological group on the basis of mechanism of action.
Non-proprietary name: Roflumilast.
Pharmacokinetics
Absorption: Roflumilast has an oral bioavailability is 80%.
Distribution: Roflumilast has a volume of distribution is 2.9lit/kg. plasma protein binding is 99%.
Elimination: it is metabolised via via liver, plasma half-life is 17-30hr, renal excretion is 70%.
Advertisement
Indications
Roflumilast is primarily indicated in conditions like Chronic bronchitis, Chronic obstructive pulmonary disease.
Contraindications
Roflumilast is contraindicated in conditions like Hepatic impairment, Hypersensitivity.
Dosage
Roflumilast's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 500 ug | 500 ug | Every 24h | PO | |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Roflumilast produces potentially life-threatening effects which include Suicidal ideation. Careful monitoring is needed with proper medical management.
The signs and symptoms that are produced after acute overdosage of Roflumilast are aterial hypotension, Dizziness, Palpitations , Headache, GI disturbances.
Roflumilast is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Decreased appetite, Diarrhea, Headache, Insomnia, Nausea, Weight loss.
Warnings / Precautions
Available Brands
None recorded.
Drug Classification
- 1.25.1.1 — Oral/Parenteral antiasthmatics